Clinical Trials Directory

Trials / Unknown

UnknownNCT05323318

Neuropsychological Sequelae and Long COVID-19 Fatigue

Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Centro Hospitalar Universitario do Algarve · Academic / Other
Sex
All
Age
18 Years – 95 Years
Healthy volunteers

Summary

An association of fatigue with post-viral neuropsychological disturbs has been reported. Among patients hospitalized with COVID-19 there is an increased incidence of anxiety and depression symptoms. In addition, a quarter of patients experience at least mild symptoms of acute post traumatic stress disorder. (Mazza, M. G. et al 2020). The prevalence of chronic fatigue syndrome had a correlation with post-traumatic stress disorder (PTSD) in a study conducted after the outbreak of the COVID-19 in Iran (Silmani et al, 2021), that showed 5.8% of subjects suffering from PTSD after 6 months of SARS-CoV-2 infection onset. In this Study we propose to use a tool to quantify the degree of physical and psychological fatigue in post-COVID-19 patients, and assess the correlation of fatigue with the neuropsychiatric sequelae in hospitalized and non hospitalized patients.

Detailed description

This study will address the neuropsychiatric sequelae that remain for at least 6 months after SARS-CoV-2 acute infection, as depression, anxiety and/or post-traumatic stress disorder. The patiensts will be assessed at the post-COVID-19 outpatient clinics of five Portuguese Hospitals. In the first visit (T1) will be collected the demographic characteristics; the medical history; and the screening of acute disease symptoms and severity. In the second visit (T2), the time frame will be at least 6 months after the positive test and no longer than 9 months, a set of structured questionnaires will be provided, including: the Chalder Fatigue Scale, Anxiety and Depression Hospital Scale (HADS), The Posttraumatic Stress Symptoms-14 (PTSS-14) adapted to COVID-19 and the EuroQol 5-Dimensions (EQ-5D).

Conditions

Interventions

TypeNameDescription
OTHERNeuropsychological SequelaeNeuropsychological Sequelae after SARS-CoV-2 symtomatic infection

Timeline

Start date
2022-04-01
Primary completion
2023-03-30
Completion
2023-04-30
First posted
2022-04-12
Last updated
2023-03-14

Locations

6 sites across 1 country: Portugal

Source: ClinicalTrials.gov record NCT05323318. Inclusion in this directory is not an endorsement.